Monitor the pace of selling by the securityholders, particularly Victus Global Multi-Asset Fund (the largest holder at 9.99% pre-offering), as overhang from the registered shares could pressure the stock. The company's cash runway is short (approximately 2-3 months at the current burn rate), so watch for additional financing announcements or progress toward the planned 510(k) submission.
How similar events traded
Executive Summary
Conexeu Sciences Inc. filed an S-1 registration statement to register 7,733,722 shares of common stock for resale by selling securityholders. The shares consist of 1,416,667 shares issued in an October 2026 private placement, 1,416,667 shares issuable upon exercise of $3.00 warrants, 4,355,388 shares issuable upon exercise of $2.30 warrants, and 545,000 shares issued upon prior warrant exercises. The company will not receive proceeds from the resale but could receive up to $14.3 million if all warrants are exercised for cash. Conexeu is a pre-revenue early-stage medical device company with one preclinical device candidate (CXU scaffold) and has a going concern qualification with $2.0 million cash as of July 31, 2026.
Key Facts
- S-1 registers 7,733,722 shares for resale by selling securityholders, representing 24.9% of the 31,089,865 shares outstanding as of November 19, 2026
- Company will not receive proceeds from resales but could receive up to $10,017,392 from $2.30 warrant exercises and $4,250,001 from $3.00 warrant exercises
- Conexeu is pre-revenue with no approved products; its only device candidate (CXU scaffold) is in preclinical development
- Net loss of $11.7 million for the nine months ended July 31, 2026, compared to $2.0 million in the prior-year period
- Cash and cash equivalents of $1.97 million as of July 31, 2026, with a going concern qualification and estimated monthly cash burn of $0.87 million
- Accumulated deficit of $16.3 million as of July 31, 2026
- Material weakness in internal control over financial reporting identified
- 12 offering/registration filings in the last 24 months, indicating frequent capital raising
Financial Impact
Potential dilution of up to 24.9% of current shares outstanding from the registered resale shares; potential cash proceeds to the company of up to $14.3 million if all warrants are exercised
Risk Factors
- Potential significant dilution from the resale of 7.7 million registered shares (24.9% of outstanding)
- Going concern risk with only $2.0 million cash and a monthly burn rate of $0.87 million
- No approved products or revenue; sole device candidate is in preclinical development with uncertain regulatory pathway
- Material weakness in internal controls over financial reporting
- Frequent equity issuances (12 offerings in 24 months) suggest ongoing capital needs
Market Snapshot
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001062993-26-006205 |
| Exhibit: exhibit10-34.htm | 0001062993-26-006205 |
| Exhibit: exhibitfilingfees.htm | 0001062993-26-006205 |
| Exhibit: exhibit5-1.htm | 0001062993-26-006205 |
| Exhibit: exhibit23-3.htm | 0001062993-26-006205 |
| Exhibit: exhibit23-1.htm | 0001062993-26-006205 |
| Document: 0001062993-26-006205-index-headers.html | 0001062993-26-006205 |
| Document: 0001062993-26-006205-index.html | 0001062993-26-006205 |
| Document: 0001062993-26-006205.txt | 0001062993-26-006205 |
Track record
10 reports on CNXU
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 19, 20262d ago S-1 Bearish 5/10 Viewing Entry $2.38 Now $1.55 +34.87% settles Nov 30
- Nov 16, 20265d ago 8-K Neutral 2/10 Entry $2.00 Now $1.55 −22.50% settles Nov 24
- Oct 27, 202625d ago 8-K Bearish 5/10 Entry $2.88 to $2.22 Now $1.55 +46.18% ▲ +22.92% +22.20% vs SPY
- Oct 20, 20264w ago 8-K Bearish 6/10 Entry $3.33 to $2.95 Now $1.55 +53.45% ▲ +11.41% +10.97% vs SPY
- Oct 15, 20265w ago Press Release Mixed 5/10 Entry $3.06 to $3.10 Now $1.55 −49.35% ▲ +1.31% +1.74% vs SPY
- Oct 6, 20266w ago Press Release Neutral 3/10 Entry $3.66 to $3.31 Now $1.55 −57.65% ▼ −9.56% −9.42% vs SPY
- Jun 29, 202620w ago 3 Neutral 2/10 Entry $10.24 to $10.80 Now $1.55 −84.86% ▲ +5.47% +4.08% vs SPY
- Jun 23, 202621w ago Insider Buy Neutral 2/10 Entry $10.69 to $10.26 Now $1.55 −85.50% ▼ −4.02% −5.73% vs SPY
- Jun 3, 202624w ago Press Release Neutral 2/10 Entry $16.85 to $13.02 Now $1.55 −90.80% ▼ −22.73% −18.91% vs SPY
- May 14, 202627w ago Insider Cluster Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers